Esperion Therapeutics
ESPR
#6169
Rank
A$1.33 B
Marketcap
A$5.62
Share price
-1.58%
Change (1 day)
8.44%
Change (1 year)

Esperion Therapeutics (ESPR) - Total liabilities

Total liabilities on the balance sheet as of September 2025 : A$1.22 Billion

According to Esperion Therapeutics's latest financial reports the company's total liabilities are A$1.22 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Esperion Therapeutics - Total liabilities on balance sheet (from 2001 to 2025)

Total liabilities by year

Year Total liabilities Change
2024-12-31A$1.17 B21.43%
2023-12-31A$0.96 B15.44%
2022-12-31A$0.84 B5.28%
2021-12-31A$0.79 B36.54%
2020-12-31A$0.58 B110.38%
2019-12-31A$0.27 B204.2%
2018-12-31A$91.32 M115.1%
2017-12-31A$42.45 M84.23%
2016-12-31A$23.04 M101.94%
2015-12-31A$11.41 M-3.94%
2014-12-31A$11.87 M152.11%
2013-12-31A$4.71 M-80.18%
2012-12-31A$23.77 M195.91%
2011-12-31A$8.03 M
2002-12-31A$22.47 M-3.13%
2001-12-31A$23.2 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Ultragenyx Pharmaceutical
RARE
A$1.76 B 44.02%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
A$2.34 B 91.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
A$174.08 B 14,081.71%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
A$13.86 B 1,029.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Amicus Therapeutics
FOLD
A$0.96 B-21.71%๐Ÿ‡บ๐Ÿ‡ธ USA
Lexicon Pharmaceuticals
LXRX
A$0.12 B-89.48%๐Ÿ‡บ๐Ÿ‡ธ USA